Table 2

Secondary objectives and outcome measures

Secondary objectiveOutcome measureTime point of outcome measured
Determine which pathway leads to more people on OST who are confirmed HCV RNA positive being treated and cured.Percentage of patients achieving SVR12 from the patient population that tested positive for HCV in each arm (modified intention to treat).At least 12 weeks after participants finish their HCV treatment.
Evaluate if the pharmacist-intervention pathway is more cost-effective than the education-only pathway, from the perspective of the NHS (UK) and Medicare (Australia).Incremental cost-effectiveness ratio to consider the epidemiological impact of scaling up the intervention to all pharmacies in a specific setting in Australia, Scotland and Wales; and cost-benefit calculations. Lifetime horizon between 10–20 years.End of Study.
Determine which pathway leads to more people on OST being tested for HCV.Proportion of patients being tested for HCV in each arm.End of study.
Compare adherence and persistence to HCV therapy in each pathway.Proportion of patients adhering to therapy in each arm (taking ≥85% of prescribed tablets) as reported in the observed therapy adherence log.End of study.
Assess the impact of baseline blood tests on treatment decisions.Proportion of patients in whom changes in therapy are advised due to blood test results, as recorded at start of HCV therapy.Prior to treatment.
  • HCV, hepatitis C virus; NHS, national health service; OST, opiate substitution therapy; SVR12, sustained viral response at 12 weeks.